Nancy I Kerkvliet

Title: Nancy I Kerkvliet: Innovator in Autoimmune Disease Treatment

Introduction

Nancy I Kerkvliet is a prominent inventor based in Corvallis, OR (US). She has made significant contributions to the field of immunology, particularly in the treatment of autoimmune diseases. With a total of 2 patents, her work focuses on the development of small molecule ligands that activate the aryl hydrocarbon receptor (AhR).

Latest Patents

Kerkvliet's latest patents include innovative methods for treating autoimmune diseases using AhR ligands. One patent discloses small molecule AhR ligands that can induce the differentiation of Tr1 cells, effectively suppressing pathogenic immune responses without causing nonspecific immune suppression. Another patent outlines a composition and method for treating autoimmune diseases by administering an effective amount of an AhR ligand, such as 11-Cl-BBQ or 10-Cl-BBQ. These ligands can be administered through various routes, including topical, oral, and intravenous methods. They induce regulatory T cells (AhR-Tregs) that block the differentiation of cytotoxic T-lymphocytes, thereby preventing the development of CTL that attack host cells in conditions like graft versus host disease and type 1 diabetes.

Career Highlights

Nancy I Kerkvliet is affiliated with Oregon State University, where she continues her research and development efforts. Her work has garnered attention for its potential to revolutionize treatment options for autoimmune diseases.

Collaborations

Kerkvliet collaborates with notable colleagues, including Siva Kumar Kolluri and Sebastian Bernales, to advance her research initiatives.

Conclusion

Nancy I Kerkvliet's innovative work in the field of autoimmune disease treatment highlights her role as a leading inventor. Her patents reflect a commitment to developing effective therapies that could significantly improve patient outcomes.